explore -WSS

explore

author：knowledge 2025-09-29 13:31:18 - browse：9

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

WSS

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

AI models in health care face new federal disclosure requirements

What PEPFAR has meant on the ground in Ukraine

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Why sickle cell disease is getting the first CRISPR treatment

After sickle

focus

explore

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

STAT Madness 2024: Meet the contenders

Drug repurposing or repositioning? The language matters

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

In age of alternative facts, a scholarly course on calling out crap

Pfizer is about to make a big push in cancer. Will investors listen?

Hollywood unions extend contract negotiations for actors

Neuroscience renaissance leads to new crop of psychiatric drugs

Heart attack and stroke risk calculators need revising

Leukemia patients are helped by Syndax's new type of therapy

hotspot

SCOTUS to consider access to abortion pill mifepristone

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

STAT letters to the editor on burnt

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Pfizer is about to make a big push in cancer. Will investors listen?

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

entertainment

knowledge

focus

explore